Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erdafitinib in Patients With Advanced Solid Tumors With <i>FGFR</i> Alterations (RAGNAR): Results of Tumor-Specific Analyses and Secondary Cohorts.

JCO precision oncology·2026
Same author

Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses.

Journal of gynecologic oncology·2026
Same author

Diagnostic and therapeutic challenges in mammary and extra-mammary Paget disease: a retrospective case series.

Photodiagnosis and photodynamic therapy·2026
Same author

Ten-Year Experience in the Treatment of Cancers of Unknown Primary from Poland: From Overall Survival to Factors Influencing Response in the Prepersonalization Era.

Cancers·2026
Same author

Development of a Health-Related Quality of Life Tool for Adolescents and Young Adults With Cancer.

JAMA network open·2026
Same author

Timing of final oncologist visit and systemic treatment use near the end of life in pretreated patients with metastatic triple-negative breast cancer: a multinational cohort study.

Breast (Edinburgh, Scotland)·2026

Related Experiment Video

Updated: Apr 26, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

8.5K

Follow-up in soft tissue sarcomas.

Piotr Rutkowski1, Iwona Lugowska1

  • 1Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.

Memo
|August 5, 2014
PubMed
Summary

Effective soft tissue sarcoma (STS) follow-up relies on individualized risk assessment and efficient monitoring. Early detection of recurrent STS, particularly lung metastases, can significantly improve patient survival rates.

Keywords:
Follow-upGastrointestinal stromal tumorsRecurrencesSarcoma

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

13.7K
Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone
06:53

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Published on: September 9, 2020

2.8K

Related Experiment Videos

Last Updated: Apr 26, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

8.5K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

13.7K
Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone
06:53

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Published on: September 9, 2020

2.8K

Area of Science:

  • Oncology
  • Medical Imaging
  • Clinical Medicine

Background:

  • Soft tissue sarcomas (STS) require tailored follow-up strategies post-therapy to manage recurrence risk.
  • Advances in sarcoma treatment necessitate early detection of resectable recurrent disease for improved patient survival.

Approach:

  • The follow-up strategy emphasizes efficient observation methods based on individual recurrence risk.
  • Mandatory follow-up includes frequent history, physical examination, and chest X-rays within the first 2-3 years post-treatment.
  • Contrast-enhanced CT scans of the abdomen and pelvis are recommended for retroperitoneal or intraperitoneal STS, including gastrointestinal stromal tumors.

Key Points:

  • The majority of STS recurrences, including lung metastases and local recurrences, occur within 5 years.
  • Intensive follow-up (every 3 months) with specific examinations is crucial between 2 and 3 years post-treatment for asymptomatic patients.
  • Additional imaging studies are generally not indicated for asymptomatic patients unless symptoms arise.

Conclusions:

  • Current recommendations for STS follow-up are outlined, focusing on risk-stratified and efficient monitoring.
  • The strategy aims to detect recurrent disease at an earlier, more manageable stage, thereby prolonging patient survival.
  • Personalized follow-up protocols are essential for optimizing outcomes in soft tissue sarcoma patients.